Antitumoral effect of interleukin-12-secreting fibroblasts in a mouse model of ovarian cancer: Implications for the use of ovarian cancer biopsy- derived fibroblasts as a vehicle for regional gene therapy

Cancer Gene Therapy

Volumn 7, Issue 5, 2000, Pages 707-720

  Sanches, Raquel ^a   Kuiper, Marcel ^a   Penault Llorca, Frédérique ^b   Aunoble, Bénédicte ^a   D'Incan, Chantal ^a,c   Bignon, Yves Jean ^a,b  

^a INSERM   (France)

^b CENTRE JEAN PERRIN   (France)

^c Ctr Medico Chirurgical Maternite T   (France)

Author keywords

Fibroblasts; Gene therapy; Interleukin 12; Neo(R) marker gene; Ovarian neoplasms; Syngeneic immunocompetent mouse model of ovarian cancer

Indexed keywords

INTERLEUKIN 12; VIRUS VECTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; FEMALE; FIBROBLAST; GENE EXPRESSION; GENE THERAPY; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MARKER GENE; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALIA; MURINAE; MUS MUSCULUS; UNIDENTIFIED RETROVIRUS;

EID: 0034107011     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700162     Document Type: Article

References (53)

1. Hill C. Épidémiologie des cancers de l'ovaire. In: Lefranc J-P, ed. Tumeurs de l'Ovaire. Paris, France: Editions ESKA; 1999:25-29.
2. National Institutes of Health. Ovarian cancer: screening, treatment, and follow-up. NIH Consens Statement. 1994; 12:1-30.
3. Kuiper M, Peakman M, Farzaneh F. Ovarian tumour antigens as potential targets for immune gene therapy. Gene Ther. 1995;2:7-15.
4. Dorigo O, Berek JS. Gene therapy for ovarian cancer: development of novel treatment strategies. Int J Gynecol Cancer. 1997;7:1-13.
5. Barnes MN, Deshane JS, Rosenfeld M, Siegal GP, Curiel DT, Alvarez RD. Gene therapy and ovarian cancer: a review. Obstet Gynecol 1997;89:145-155.
6. Gomez-Navarro J, Siegal GP, Alvarez RD, Curiel DT. Gene therapy: ovarian carcinoma as the paradigm. Am J Clin Pathol. 1998;109:444-467.
7. Tong XW, Kieback DG, Ramesh R, Freeman SM. Molecular aspects of ovarian cancer: is gene therapy the solution? Hematol Oncol Clin North Am. 1999;13:109-133.
8. Hodgson CP. The vector void in gene therapy: can viral vectors and transfection be combined to permit safe, efficacious, and targeted gene therapy? Biotechnology. 1995;13:222-225.
9. Anderson WF. Human gene therapy. Nature. 1998;392:25-30.
10. Colombo MP, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today. 1994;15:48-51.
11. Musiani P, Modesti A, Giovarelli M, et al. Cytokines, tumour-cell death, and immunogenicity: a question of choice. Immunol Today. 1997;18:32-36.
12. Mackensen A, Lindemann A, Mertelsmann R. Immunostimulatory cytokines in somatic cells and gene therapy of cancer. Cytokine Growth Factor Rev. 1997;8:119-128.
13. Galea-Lauri J, Farzaneh F, Gäken J. Novel costimulators in the immune gene therapy of cancer. Cancer Gene Ther. 1996;3:202-213.
14. Freeman SM, Whartenby KA, Freeman JL, Abboud CN, Marrogi AJ. In situ use of suicide genes for cancer therapy. Semin Oncol. 1996;23:31-45.
15. Tahara H, Lotze MT. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther. 1995;2:96-106.
16. Brunda MJ, Luistro L, Rumennik L, et al. Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother Pharmacol. 1996;38(suppl):S16-S21.
17. Shurin MR, Esche C, Péron J-M, Lotze MT. Antitumor activities of IL-12 and mechanisms of action. Chem Immunol. 1997;68:153-174.
18. Golab J, Zagozdzon R. Antitumor effects of interleukin-12 in pre-clinical and early clinical studies. Int J Mol Med. 1999;3:537-544.
19. Chizzonite R, Truitt T, Desai BB, et al. IL-12 receptor: characterization of the receptor on phytohemagglutinin-activated human lymphoblasts. J Immunol. 1992;148:3117-3124.
20. Desai BB, Quinn PM, Wolitzky AG, Mongini PK, Chizzonite R, Gately MK. IL-12 receptor: distribution and regulation of receptor expression. J Immunol. 1992;148:3125-3132.
21. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood. 1994;84:4008-4027.
22. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol. 1995;13:251-276.
23. Trinchieri G. Interleukin-12 and interferon-γ: do they always go together? Am J Pathol. 1995;147:1534-1538.
24. Voest EE, Keynyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Kolkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995;87:581-586.
25. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein-10. Blood. 1996;87:3877-3882.
26. Coughlin CM, Salhany KE, Gee MS, et al. Tumor cell responses to IFNγ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity. 1998;9:25-34.
27. Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP, Harrap KR. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer. 1989;59:527-534.
28. Provencher DM, Finstad CL, Saigo PE, et al. Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer. Gynecol Oncol. 1993;50:78-83.
29. Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA. 1988;85:6460-6464.
30. Zitvogel L, Tahara H, Cai Q, et al. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum Gene Ther. 1994; 5:1493-1506.
31. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques. 1989;7:980-990.
32. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1989.
33. Cone RD, Weber-Benarous A, Baorto D, Mulligan RC. Regulated expression of a complete human β-globin gene encoded by a transmissible retrovirus vector. Mol Cell Biol. 1987;7:887-897.
34. Lotze MT, Rubin JT, Carty S, et al. Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Hum Gene Ther. 1994;5:41-55.
35. Tahara H, Lotze MT, Robbins PD, Storkus WJ, Zitvogel L. IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther. 1995;6:1607-1624.
36. Elder EM, Lotze MT, Whiteside TL. Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer. Hum Gene Ther. 1996;7:479-487.
37. Fakhrai H, Shawler DL, Van Beveren C, et al. Construction and characterization of retroviral vectors for interleukin-2 gene therapy. J Immunother. 1997;20:437-448.
38. Suminami Y, Elder EM, Lotze MT, Whiteside TL. In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine. J Immunother. 1995;17:238-248.
39. Shawler DL, Dorigo O, Gjerset RA, Royston I, Sobol RE, Fakhrai H. Comparison of gene therapy with interleukin-2 gene-modified fibroblasts and tumor cells in the murine CT-26 model of colorectal carcinoma. J Immunother. 1995; 17:201-208.
40. Kuiper M, Sanches R, Gäken JA, Bignon Y-J. Cloning and characterization of a retroviral plasmid, pCC1, for combintion suicide gene therapy. Biotechniques. 2000; 28:572-576.
41. Xu Y, Silver DF, Yang N-P, et al. Characterization of human ovarian carcinomas in a SCID mouse model. Gynecol Oncol. 1999;72:161-170.
42. Tahara H, Zeh HJ, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 1994;54:182-189.
43. Pappo I, Tahara H, Robbins PD, et al. Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy. J Surg Res. 1995;58: 218-226.
44. Zitvogel L, Tahara H, Robbins PD, et al. Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts. J Immunol. 1995;155:1393-1403.
45. Pippin BA, Rosenstein M, Jacob WF, Chiang Y, Lotze MT. Local IL-4 delivery enhances immune reactivity to murine tumors: gene therapy in combination with IL-2. Cancer Gene Ther. 1994;1:35-42.
46. Fakhrai H, Shawler DL, Gjerset R, et al. Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum Gene Ther. 1995;6:591-601.
47. Glick RP, Lichtor T, Kim TS, Ilangovan S, Cohen EP. Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo. Neurosurgery. 1995;36:548-555.
48. Tüting T, Gambotto A, Baar J, et al. Interferon-α gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for delivery in murine tumor models. Gene Ther. 1997;4:1053-1060.
49. Rakhmilevich AL, Timmins JG, Janssen K, Pohlmann EL, Sheehy MJ, Yang N-S. Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy. J Immunother. 1999;22:135-144.
50. Kerbel RS, Hawley RG. Interleukin-12: newest member of the antiangiogenesis club. J Natl Cancer Inst. 1995;87:557-559.
51. Silver DF, Hempling RE, Piver MS, Repasky EA. Effects of IL-12 on human ovarian tumors engrafted into SCID mice. Gynecol Oncol. 1999;72:154-160.
52. Veelken H, Mackensen A, Lahn M, et al. A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int J Cancer. 1997;70:269-277.
53. Sobol RE, Royston I, Fakhrai H, et al. Injection of colon carcinoma patients with autologous irradiated tumor cells and fibroblasts genetically modified to secrete interleukin-2 (IL-2): a phase I study. Hum Gene Ther. 1995;6:195-204.